Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.

[1]  Evelyn D. Lobo,et al.  Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro , 2008, AAPS PharmSci.

[2]  S. A. Watkins,et al.  Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. , 2005, Biochemistry.

[3]  Carlos L Arteaga,et al.  Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  Lewis B. Sheiner,et al.  Pharmacostatistical modeling for observational data , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[7]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[8]  R. Campbell,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2004, Bioorganic & medicinal chemistry letters.

[9]  R. Campbell,et al.  Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. , 2004, Bioorganic & medicinal chemistry letters.

[10]  P. Dijke,et al.  New insights into TGF-β–Smad signalling , 2004 .

[11]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[12]  Jin Y. Jin,et al.  Modeling of Corticosteroid Pharmacogenomics in Rat Liver Using Gene Microarrays , 2003, Journal of Pharmacology and Experimental Therapeutics.

[13]  M. Vieth,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2003, Journal of medicinal chemistry.

[14]  T. Kubota,et al.  Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer , 2002, International journal of cancer.

[15]  A. Roberts,et al.  Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. , 2001, Advances in cancer research.

[16]  M. Karlsson,et al.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[17]  R. Calvo,et al.  Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  J. Kleeff,et al.  Transfection of the type I TGF‐β receptor restores TGF‐β responsiveness in pancreatic cancer , 1998 .

[19]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[20]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[21]  J. O’Donoghue,et al.  The response of tumours with Gompertzian growth characteristics to fractionated radiotherapy. , 1997, International journal of radiation biology.

[22]  Xiao-Fan Wang,et al.  Signaling by the transforming growth factor-β receptor , 1995 .

[23]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[24]  L. Sheiner,et al.  An introduction to mixed effect modeling: Concepts, definitions, and justification , 1991 .

[25]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[26]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.